{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:47:55Z","timestamp":1790740075720,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005736","name":"Paris Diderot","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jid.2018.09.026","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T13:58:08Z","timestamp":1540475888000},"page":"725-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of S\u00e9zary Syndrome Patients"],"prefix":"10.1016","volume":"139","author":[{"given":"Armand","family":"Bensussan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Janela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thonnart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Musette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Ginhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marie-Cardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.09.026_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V97.5.1388","article-title":"CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor","volume":"97","author":"Bagot","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.09.026_bib2","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/onc.2012.269","article-title":"ENTPD1\/CD39 is a promising therapeutic target in oncology","volume":"32","author":"Bastid","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2018.09.026_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","article-title":"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jid.2018.09.026_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008397323199","article-title":"Prognostic factors in S\u00e9zary syndrome: a multivariate analysis of clinical, haematological and immunological features","volume":"9","author":"Bernengo","year":"1998","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jid.2018.09.026_bib5","doi-asserted-by":"crossref","first-page":"e1003015","DOI":"10.1080\/2162402X.2014.1003015","article-title":"CD39: a complementary target to immune checkpoints to counteract tumor-mediated immunosuppression","volume":"4","author":"Bonnefoy","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2018.09.026_bib6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2018.09.026_bib7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.09.026_bib8","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-16-3185","article-title":"Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with S\u00e9zary syndrome","volume":"23","author":"Hurabielle","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2018.09.026_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.09.026_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.09.026_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1309\/U1Y6-J4AG-5M4M-7AYV","article-title":"Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood","volume":"115","author":"Jones","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2018.09.026_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1309\/05GFG3LY3VYCDMEY","article-title":"The usefulness of CD26 in flow cytometric analysis of peripheral blood in S\u00e9zary syndrome","volume":"129","author":"Kelemen","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2018.09.026_bib13","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1158\/0008-5472.CAN-14-1456","article-title":"IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma","volume":"74","author":"Marie-Cardine","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2018.09.026_bib14","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2005-10-4239","article-title":"Significance of circulating T-cell clones in S\u00e9zary syndrome","volume":"107","author":"Ortonne","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.09.026_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18326988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18326988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:11:43Z","timestamp":1758301903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18326988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0022202X18326988"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.09.026","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of S\u00e9zary Syndrome Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}